An interventional study of Goldballoon Detachable Balloon (GOLDBAL2) in Severe Congenital Diaphragmatic Hernia, sponsored by NYU Langone Health. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment
The purpose of this pilot study is to evaluate the feasibility of using Fetoscopic Endoluminal Tracheal Occlusion (FETO) in 10 pregnant individuals carrying fetuses with severe congenital diaphragmatic hernia (CDH). FETO surgery will be performed at 27 weeks - 29 weeks and 6 days of gestation, and the fetoscopic removal of the balloon will be performed at 34 weeks - 34 weeks and 6 days of gestation. The primary endpoint is successful placement and removal of the balloon.
Exclusion Criteria:
FETO surgery will be performed at 27 weeks - 29 weeks and 6 days of gestation, and the fetoscopic removal of the balloon will be performed at 34 weeks - 34weeks and 6 days of gestation.
Device: Goldballoon Detachable Balloon (GOLDBAL2)
GOLDBAL2 will be inserted into the fetal trachea and deployed with the Delivery Microcatheter (BALTACCI-BDPE100).
Number of successful balloon placements at age 27w0d - 29w6d and removal at 34 weeks of gestation
Time frame: Up to 35 weeks
Difference between the relative lung volume (o/e LHR and o/e TLV)
Fetal lung growth will be calculated by the difference between the relative lung volume (observed-to-expected (o/e) lung-to-head ratio (LHR) and o/e total lung volume (TLV)) measured before and after FETO
Time frame: Baseline, removal of balloon (up to 35 weeks)
Plan to share: Yes — The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: jose.peiro@nyulangone.org. Besides the study publications, by FDA regulation, the data will be shared with the NAFTNet FETO registry, which will involve all of the individual participant data collected during the trial, after deidentification. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.
Supporting information: Study protocol, Sap
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hernias, Diaphragmatic, Congenital→
NYU Langone Health